Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (231-240 of 303) with videos related to

Pageof 31
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 1, 2013
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapyJin Seok Ahn, Ki Hyeong Lee, Jong-Mu Sun, et al.
Plos Genetics|August 22, 2015
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid CancerJun Ho Ji, Young Lyun Oh, Mineui Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2015
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancerSun Min Lim, Woong Youn Chung, Kee-Hyun Nam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 11, 2016
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung CancerHaa-Na Song, Ki Sun Jung, Kwai Han Yoo, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapyByung Jo Park, Jong Ho Cho, Jung Hee Lee, et al.
Clinical Pharmacology in Drug Development|January 19, 2018
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLCEng-Huat Tan, Wan-Teck Lim, Myung-Ju Ahn, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2025
The role of APOBEC in early-stage epidermal growth factor receptor-mutant non-small cell lung cancerHyun Ae Jung, Jinyeong Lim, Yoon-La Choi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2017
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung CancerJong-Mu Sun, Jae Myung Noh, Dongryul Oh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)Hyun Ae Jung, Miso Kim, Hae Su Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2012
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)Jun Ho Ji, , Tak Yun, et al.
Pageof 31

Showing results (231-240 of 303) with videos related to

Sort By:
Pageof 31
Lung Cancer (Amsterdam, Netherlands)|October 1, 2013
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapyJin Seok Ahn, Ki Hyeong Lee, Jong-Mu Sun, et al.
Plos Genetics|August 22, 2015
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid CancerJun Ho Ji, Young Lyun Oh, Mineui Hong, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2015
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancerSun Min Lim, Woong Youn Chung, Kee-Hyun Nam, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 11, 2016
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung CancerHaa-Na Song, Ki Sun Jung, Kwai Han Yoo, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapyByung Jo Park, Jong Ho Cho, Jung Hee Lee, et al.
Clinical Pharmacology in Drug Development|January 19, 2018
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLCEng-Huat Tan, Wan-Teck Lim, Myung-Ju Ahn, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2025
The role of APOBEC in early-stage epidermal growth factor receptor-mutant non-small cell lung cancerHyun Ae Jung, Jinyeong Lim, Yoon-La Choi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2017
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung CancerJong-Mu Sun, Jae Myung Noh, Dongryul Oh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)Hyun Ae Jung, Miso Kim, Hae Su Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2012
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)Jun Ho Ji, , Tak Yun, et al.
Pageof 31